Global Fund to Fight AIDS, Tuberculosis and Malaria

Richard Foord Excerpts

Tuesday 4th November 2025 Westminster Hall

[Dr Chambers]

I completely agree about the importance of demonstrating international leadership on this issue. If international support declines, from us and other countries, an additional 10 million new HIV infections, including up to 880,000 in children, could occur by 2030. Those are preventable deaths—people who could be alive this time next year if we choose differently and maintain funding.

Tuberculosis, often called a Victorian superbug, is on the rise again, with cases in England up 13% last year. Globally, it remains one of the leading infectious killers. It is largely preventable, treatable, and curable in the vast majority of cases, yet is too often neglected. Malaria is a microscopic parasite, spread by something as small as a mosquito, that continues to kill half a million people a year. There is a saying, “If you think you are too small to make a difference, you have never spent the night in a tent with a mosquito.” We know what works: mosquito nets, repellents, rapid tests and education. The challenge is not the science but the access. The tools exist but too many communities cannot afford or reach them.

When it comes to global public health,

“Nobody wins unless everybody wins.”

Those are not my words but Bruce Springsteen’s. They apply just as much to global health as they do to any other struggle. If we allow international health systems to weaken and turn our backs on collaboration, we are failing not only others but ourselves. Every time we strengthen a health system abroad, we strengthen Britain’s safety at home. We reduce the risk of the next pandemic reaching our shores, protect supply chains, stabilise economies and open new opportunities for trade and innovation.

If we invest now, we can cement the UK’s reputation as a global leader in health innovation, not just through our laboratories and universities, but through partnerships such as the Global Fund that translate research into real-world impact. British expertise in vaccine development, diagnostics and data science already help to shape programmes that have saved lives across the world. Continued investment allows us to share knowledge, strengthen health systems and, in doing so, build influence and resilience that benefit the UK and our global partners.

We also need to be honest about the wider picture. The UK’s official development assistance budget has already been reduced from 0.7% to 0.5% of national income. The Government are now reducing it further, to around 0.3% by 2027. The Fleming Fund, which monitors and helps to tackle antimicrobial resistance, has been scaled back, and the UK’s contribution to Gavi, the Vaccine Alliance has fallen from about £1.65 billion to £1.25 billion for the next funding cycle, which is a real-terms reduction of roughly 40%.

Taken together, those decisions risk sending a message that Britain is retreating from its proud record of global health leadership. If we are serious about being a world leader in science, public health and international development, maintaining our commitment to the Global Fund is one of the clearest and most effective ways to show it. A rushed transition from global aid to self-financing, forced by rapid funding reductions, will result in direct harm through reduced healthcare, stock-outs of essential medicines and untimely deaths. When this is done in the context of infectious disease, the long-term cost will rise in exchange for short-term savings.

[Richard Foord (Honiton and Sidmouth) (LD)]

My hon. Friend talks about infectious disease. The cost of the malaria vaccine is now thought to be just under $5 a dose, which is amazing purchasing power. By contrast, the UK, under the last Government, who are not represented here today, was spending 29% of UK aid on in-country donor costs—that is, on hotel accommodation. Does he think this money could be better spent?